Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 400 of 1467 entries
View as:

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

Phase: N/A Priority: Normal
NCT ID: NCT00825019 Org: User:
Start: 09/30/03 End: 12/31/04 Due: 12/31/05

Drotaverine in Dysmenorrhoea Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00292747 Org: User:
Start: 05/25/05 End: 02/28/06 Due: 02/28/07

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01061736 Org: User:
Start: 03/31/10 End: 10/31/13 Due: 10/31/14

Once Daily Given Alfuzosin in the Treatment of BPH

Phase: N/A Priority: Normal
NCT ID: NCT00637715 Org: User:
Start: 10/31/03 End: 12/31/04 Due: 12/31/05

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

Phase: N/A Priority: Normal
NCT ID: NCT00763815 Org: User:
Start: 09/30/08 End: 06/30/11 Due: 06/30/12

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Phase: N/A Priority: Normal
NCT ID: NCT01644188 Org: User:
Start: 08/31/12 End: 07/31/15 Due: 07/31/16

Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing

Phase: N/A Priority: Normal
NCT ID: NCT00443612 Org: User:
Start: 09/30/06 End: - Due: -

Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05795907 Org: User:
Start: 11/30/20 End: 07/20/21 Due: 07/20/22

Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00135083 Org: User:
Start: 08/31/04 End: 11/30/07 Due: 11/30/08

Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Photo Avaluation

Phase: N/A Priority: Normal
NCT ID: NCT00785720 Org: User:
Start: 08/31/08 End: 09/30/08 Due: 09/30/09

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05013554 Org: User:
Start: 08/16/21 End: 01/15/24 Due: 01/15/25

Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®

Phase: N/A Priority: Normal
NCT ID: NCT01195454 Org: User:
Start: 08/31/10 End: 12/31/10 Due: 12/31/11

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02441894 Org: User:
Start: 04/30/15 End: 11/30/16 Due: 11/30/17

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT03767543 Org: User:
Start: 03/11/19 End: 10/23/20 Due: 10/23/21

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase: N/A Priority: Normal
NCT ID: NCT04661033 Org: User:
Start: 09/09/21 End: 06/26/23 Due: 06/26/24

Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00403624 Org: User:
Start: 07/31/01 End: 11/30/05 Due: 11/30/06

Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01527929 Org: User:
Start: 04/30/12 End: 11/30/13 Due: 11/30/14

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia

Phase: N/A Priority: Normal
NCT ID: NCT00253968 Org: User:
Start: 11/30/05 End: 01/31/08 Due: 01/31/09

Amisulpride in Schizophrenic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00331981 Org: User:
Start: 02/29/04 End: - Due: -

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Phase: N/A Priority: Normal
NCT ID: NCT02991469 Org: User:
Start: 08/09/18 End: 02/19/29 Due: 02/19/30

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Phase: N/A Priority: Normal
NCT ID: NCT06834360 Org: User:
Start: 02/06/25 End: 12/13/27 Due: 12/13/28

A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05630547 Org: User:
Start: 12/19/22 End: 11/21/24 Due: 11/21/25

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Phase: N/A Priority: Normal
NCT ID: NCT02476006 Org: User:
Start: 06/23/15 End: 04/12/19 Due: 04/12/20

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

Phase: N/A Priority: Normal
NCT ID: NCT01223131 Org: User:
Start: 02/28/11 End: 03/31/14 Due: 03/31/15

Observational Study Describing the Immune Profile Induced By Pertussis Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT03147898 Org: User:
Start: 04/12/17 End: 07/09/18 Due: 07/09/19